CIK 0001447028 · Non-accelerated filer<br>Smaller reporting company
Arbutus Biopharma Corp
Sign in to watch- Ticker
- ABUS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980597776
- Phone
- 604-419-3200
- Business address
- 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
- Former names
- TEKMIRA PHARMACEUTICALS CORP, TEKMIRA PHARMACEUTICALS Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-01 | McElhaugh Michael J. Chief Business Officer | Grant or award | +83,700 | 1,391,157 | ||
| 2023-02-01 | McElhaugh Michael J. Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +334,700 | 334,700 | ||
| 2023-02-01 | Sofia Michael J. Chief Scientific Officer | Grant or award | +82,200 | 1,385,603 | ||
| 2023-02-01 | Sofia Michael J. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +328,700 | 328,700 | ||
| 2023-02-01 | HASTINGS DAVID C Chief Financial Officer | Grant or award | +79,000 | 79,000 | ||
| 2023-02-01 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +316,000 | 316,000 | ||
| 2023-02-01 | Collier William H. President and CEO | Grant or award | +216,500 | 216,500 | ||
| 2023-02-01 | Collier William H. President and CEO | Grant or award · Stock Option (Right to Buy) | +866,000 | 866,000 | ||
| 2023-02-01 | Howard Elizabeth EVP, GC, Compliance | Grant or award | +69,700 | 86,024 | ||
| 2023-02-01 | Howard Elizabeth EVP, GC, Compliance | Grant or award · Stock Option (Right to Buy) | +278,700 | 278,700 | ||
| 2022-05-25 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-05-25 | BURGESS DANIEL D Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-05-25 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-05-25 | Torti Frank Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-05-25 | Tran Tram Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-05-25 | MANCHESTER KEITH S Director | Grant or award · Stock Option (Right to Buy) | +41,000 | 41,000 | ||
| 2022-01-20 | Collier William H. President and CEO | Grant or award · Stock Option (Right to Buy) | +787,550 | $2.81 | $2.2M | 787,550 |
| 2022-01-20 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +285,000 | $2.81 | $801K | 285,000 |
| 2022-01-20 | Howard Elizabeth Chief Compliance Officer | Grant or award · Stock Option (Right to Buy) | +237,500 | $2.81 | $667K | 237,500 |
| 2022-01-20 | Sofia Michael J. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +285,000 | $2.81 | $801K | 285,000 |
Page 5 of 8 · 141 trades